



**Joe M O'Sullivan**

**Kontakt**

Joe M O'Sullivan

## Publikationen (8)

Schooser B, van der Beek N, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, Hundsberger T, Kornblum C, Kruijshaar M, Laforet P, Mengel E, Mongini T, Orlikowski D, Parenti G, Pijnappel W, Roberts M, Scherer T, Toscano A, Vissing J, O'Sullivan J, van Doorn P, Wenninger S, van der Ploeg A. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. *Eur J Neurol* 2024:e16383.

Omlin A, Ryan C, Rubin M, Roach M, Reiter R, Pritchard C, Poon D, Parker C, Padhani A, O'Sullivan J, Ost P, Oh W, Murthy V, Murphy D, Mrabti H, Mottet N, Morris M, Saad F, Sade J, Zapatero A, van Oort I, Türkeri L, Tombal B, Taplin M, Sydes M, Sweeney C, Suzuki H, Steuber T, Sternberg C, Soule H, Smith M, Small E, Shore N, Scher H, Sartor O, Morgans A, Millman R, Evans C, Efstathiou E, Eeles R, Duran I, Drake C, de Bono J, Davis I, Clarke N, Chi K, Bristow R, Briganti A, Bossi A, Bjartell A, Beltran H, Beer T, Attard G, Fanti S, Feng F, Maluf F, Logothetis C, Leibowitz R, Khauli R, Kantoff P, Kanesvaran R, James N, Hussain M, Hofman M, Higano C, Heinrich D, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Gillessen S. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol* 2020; 77:508-547.

Saad F, Carles J, Seger M, Reeves J, Wirth M, Miller K, Nilsson S, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. *Clin Genitourin Cancer* 2019; 17:348-355.e5.

Heidenreich A, Nilsson S, Seger M, Reeves J, Miller K, Wirth M, Carles J, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. *BMC cancer* 2019; 19:12.

Fanti S, Montironi R, Ost P, O'Sullivan J, Padhani A, Schalken J, Scher H, Tombal B, van Moorselaar R, Van Poppel H, Vargas H, Walz J, Weber W, Wester H, Lecouvet F, Hicks R, Herrmann K, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, de Bono J, Fizazi K, Gillessen Sommer S, Gledhill S, Haberkorn U, Oyen W. Consensus on molecular imaging and theranostics in prostate cancer. *Lancet Oncol* 2018; 19:e696-e708.

Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, Jonnada S, Gannon M, Gale J, Eswar C, Douis H, Din O, Birtle A, Bahl A, Khaksar S, Lester J, O'Sullivan J, Sydes M, Parmar M, Tran A, Srihari N, Sheehan D, Pudney D, Pedley I, Parikh O, Alonzi R, Amos C, Thalmann G, Chowdhury S, Attard G, Ritchie A, Ali A, Hoyle A, Clarke N, Brawley C, James N, Cross W, Dearnaley D, Gillessen Sommer S, Russell J, Millman R, Matheson D, Mason M, Malik Z, Langley R, Jones R, Gilson C, Parker C. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet* 2018; 392:2353-2366.

Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. *Lancet Oncol* 2016; 17:1306-16.

Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasili V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. *Future Oncol* 2014; 10:219-31.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)